Prince Edward Island College of Pharmacists
Regulating the practice of pharmacy in the province so as to promote a high standard and safeguard the welfare of the public with regard to pharmaceutical service.Useful Links
- Institute for Safe Medication Practices (ISMP)
- Canadian Pharmacists ASSOCIATION
- Canadian Society of Hospital Pharmacists
- Pharmacy Examining Board of Canada
- Canadian Association of Pharmacy Students and Interns
- Prince Edward Island Pharmacists Association
- National Association of Pharmacy Regulating Authorities
- Canadian Association of Pharmacy Technicians
Complaints and Discipline
NEWS & EVENTS
Treatment of Opioid Dependence Practice Directives for Community Pharmacies-Updated
The PEI College of Pharmacists has completed a review of the Methadone Maintenance Treatment Practice Directives and the final document is now available. The document receives a new name to reflect the addition of buprenorphine in the practice directives. The Practice Directives can be found on the PEI College of Pharmaicsts website under the Pharmacy Practice tab or by selecting the link below.
Treatment of Opioid Dependence Practice Directives for Community Pharmacies
Jurisprudence Exam Sitting Dates
The spring sitting of the PEI Jurisprudence Exam will be held a the PEI College of Pharmacists office from 9:30-11:30 on June 10, 2016. More information regarding registration will be availble in the near future.
Changes to Renewal Deadline
Changes to the registration renewal deadline will be in effect for 2016/2017 renewal year. See the Island Capsule newsletter for more information.
National Pharmacy Technician Bridging Program
The deadline for registration for the Winter 2016 Bridging courses, beginning in January 2016, is December 17, 2015. For more information on how to apply, please visit the Selkirk College website
CellCept (mycophenolate mofetil) and MYFORTIC (mycophenolate sodium) - Serious Risk of Teratogenicity in Mycophenolate-Containing Products
Fourteen Health Products Manufactured by Hospira- Incorrect, Outdated or Missing Labelling Information
Alveda Atropine Injection BP 0.4 mg/mL - Recall of One Lot Due to the Same Barcode as Alveda Epinephrine Injection USP 1 mg/mL
Physicians, Hospitals, Hospital Pharmacists, Long Term Care Facilities, Paramedics/Emergency Services, Retail Pharmacies, Medical Clinics and Dentists.
BRAVELLE (75 IU urofollitropin for injection, purified) - Recalled lots due to Reduced Therapeutic Effect
Ferring Inc. Canada, in consultation with Health Canada, would like to inform health care professionals of a voluntary recall of four (4) lots of BRAVELLE. The recall is due to reduced potency of the product detected during routine stability testing.
The labels on the product and the package insert currently being distributed by Hospira do not reflect the most up-to-date information and warnings. The missing information and warnings may increase the risk to patients and may result in significant patient harm requiring medical intervention. Specifically, these warnings are detailed below:
Humalog (insulin lispro) KwikPen 200 Units/mL - Information on Correct Use to Minimize Medication Errors
Key messages Co-administration of repaglinide and clopidogrel (a CYP2C8 inhibitor) may lead to a significant decrease in blood glucose levels due to a drug-drug interaction. The concomitant use of repaglinide and clopidogrel is now contraindicated. The prescriber information for GLUCONORM (repaglinide) has been updated. The prescriber information for PLAVIX (clopidogrel) is currently being updated. The prescriber information for the generic products will be updated (see Products affected).